Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS.
Engelhardt EG, Schmitz RSJM, Gerritsma MA, Sondermeijer CMT, Verschuur E, Houtzager JHE, Griffioen R, Bijker N, Mann RM, Retèl V, van Duijnhoven FH, Wesseling J, Bleiker EMA; Grand Challenge PRECISION Consortium. Engelhardt EG, et al. Breast. 2024 Oct;77:103764. doi: 10.1016/j.breast.2024.103764. Epub 2024 Jul 2. Breast. 2024. PMID: 38970983 Free PMC article.
Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Schmitz RSJM, Engelhardt EG, Gerritsma MA, Sondermeijer CMT, Verschuur E, Houtzager J, Griffioen R, Retèl V, Bijker N, Mann RM, van Duijnhoven F, Wesseling J, Bleiker EMA; Grand Challenge PRECISION Consortium. Schmitz RSJM, et al. Eur J Cancer. 2023 Oct;192:113276. doi: 10.1016/j.ejca.2023.113276. Epub 2023 Aug 4. Eur J Cancer. 2023. PMID: 37657228 Free PMC article.
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC).
Meertens M, Muntinghe-Wagenaar MB, Sikkema BJ, Lopez-Yurda M, Retèl VP, Paats MS, Ter Heine R, Schuuring E, Timens W, Touw DJ, van Boven JFM, de Langen AJ, Hashemi SMS, Hendriks LEL, Croes S, van den Heuvel MM, Dingemans AC, Mathijssen RHJ, Smit EF, Huitema ADR, Steeghs N, van der Wekken AJ. Meertens M, et al. Among authors: retel vp. Front Oncol. 2023 Mar 9;13:1136221. doi: 10.3389/fonc.2023.1136221. eCollection 2023. Front Oncol. 2023. PMID: 36969063 Free PMC article.
"One more chance to survive": the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy-a qualitative study and recommendations for future care.
Egeler MD, Boomstra E, Rohaan MW, Van den Heuvel NMJ, Fraterman I, Delfos M, van de Poll-Franse LV, Borch TH, Svane IM, Haanen JBAG, Retèl VP, Boekhout AH. Egeler MD, et al. Among authors: retel vp. J Cancer Surviv. 2025 Feb;19(1):109-120. doi: 10.1007/s11764-023-01452-8. Epub 2023 Aug 22. J Cancer Surviv. 2025. PMID: 37606816
Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.
Kramer A, Greuter MJE, Schraa SJ, Vink GR, Phallen J, Velculescu VE, Meijer GA, van den Broek D, Koopman M, Roodhart JML, Fijneman RJA, Retèl VP, Coupé VMH. Kramer A, et al. Among authors: retel vp. Ther Adv Med Oncol. 2024 Aug 21;16:17588359241266164. doi: 10.1177/17588359241266164. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39175989 Free PMC article.
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
Mfumbilwa ZA, Simons MJHG, Ramaekers B, Retèl VP, Mankor JM, Groen HJM, Aerts JGJV, Joore M, Wilschut JA, Coupé VMH. Mfumbilwa ZA, et al. Among authors: retel vp. Pharmacoeconomics. 2024 Apr;42(4):419-434. doi: 10.1007/s40273-023-01344-w. Epub 2024 Jan 9. Pharmacoeconomics. 2024. PMID: 38194023 Free PMC article.
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
Bueno-de-Mesquita JM, van Harten WH, Retel VP, van 't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC. Bueno-de-Mesquita JM, et al. Among authors: retel vp. Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26. Lancet Oncol. 2007. PMID: 18042430
119 results